Abstract
Objective: To assess the efficacy of Azithromycin, a macrolids antibiotic, againsst experimentally induced toxopiasmosis in marine model Design: Experimental study. Setting: Department of Microbiology, Nineveh College of Medicine, from October 2004 to November 2005. Results: The efficacy of Azithromycin against Toxoplasma gondii was examined in murine models of infection with a moderately virulent strain. Forty white Albino mice inoculated by mouth with 2x 10 cysts, 20 mice were treated with Azithromycin at dose of 250 mg/kg /day for 90 days. Drug treatment was initiated 30 days after infection (chronic infection). Treatment with Azithromycin significantly enhanced survival and reduced the brain cyst burden as compared with untreated (control) group of mice. Since 80% of treated mice were cornp>letely cured from toxopiasmosis as their brain were free of Toxoplasma tissue cysts either microscopically or by bioassay. Conclusion: The results warrant clinical evaluation of Azithromycin in the treatment of toxopiasmosis in both immunocompetent and immunocompromised patients.
Highlights
Summary
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
